Factors Associated with Extended-spectrum β-lactamase-producing Enterobacteria Isolated from Respiratory Samples

Objective Although extended-spectrum β-lactamase (ESBL)-producing bacteria are a global threat, as they may cause respiratory infection, the factors associated with the isolation of these bacteria from sputum remain unclear. We therefore explored the factors related to ESBL-producing Klebsiella pneu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Internal Medicine 2023/07/15, Vol.62(14), pp.2043-2050
Hauptverfasser: Matsumoto, Hiroyuki, Komiya, Kosaku, Ichihara, Shogo, Nagaoka, Yuhei, Yamanaka, Marimu, Nishiyama, Yoshiki, Hiramatsu, Kazufumi, Kadota, Jun-ichi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2050
container_issue 14
container_start_page 2043
container_title Internal Medicine
container_volume 62
creator Matsumoto, Hiroyuki
Komiya, Kosaku
Ichihara, Shogo
Nagaoka, Yuhei
Yamanaka, Marimu
Nishiyama, Yoshiki
Hiramatsu, Kazufumi
Kadota, Jun-ichi
description Objective Although extended-spectrum β-lactamase (ESBL)-producing bacteria are a global threat, as they may cause respiratory infection, the factors associated with the isolation of these bacteria from sputum remain unclear. We therefore explored the factors related to ESBL-producing Klebsiella pneumoniae and Escherichia coli isolated from sputum samples. Methods This study included consecutive patients admitted to our department from 2010 to 2021 with K. pneumoniae or E. coli isolated from their sputum. The patients were categorized into ESBL-producing and non-ESBL-producing groups, and the factors associated with ESBL-producing bacteria isolation were assessed using a binomial logistic regression analysis. Results We included 82 patients, and ESBL-producing pathogens were isolated from 23 (28%). The usage rates of cephem [odds ratio (OR) 4.000, 95% confidence interval (CI) 1.402-11.409, p=0.010], quinolone (OR 2.961, 95% CI 1.097-7.996, p=0.032), and macrolide (OR 4.273, 95% CI 1.518-12.028, p=0.006) in the past year were significantly higher in the ESBL-producing group than in the non-ESBL-producing group. The multivariate analysis revealed that the applications of cephem (adjusted OR: 4.130, 95% CI: 1.233-13.830, p=0.021) and macrolide (adjusted OR: 6.365, 95% CI: 1.922-21.077, p=0.002) was independently associated with the isolation of ESBL-producing bacteria. Conclusion A history of cephem and macrolide use can be considered a risk factor for ESBL-producing bacteria isolation from sputum samples. Physicians need to consider these risk factors when determining antibiotics for the treatment of patients with respiratory infections.
doi_str_mv 10.2169/internalmedicine.0690-22
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10400397</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2850466762</sourcerecordid><originalsourceid>FETCH-LOGICAL-c556t-66fc1464c6f49365298bfa0c743722732e27691ca8b2c95b05c5cf42c14ab6313</originalsourceid><addsrcrecordid>eNplkd1u1DAQhS0EosvCK6BI3HCT4vg3vkJVtYVKlSrxc205zmTXqyRObafQ1-JBeCYcdllBuRlfzDdnjucgVFT4nFRCvXNjgjCafoDWWTfCORYKl4Q8QauKMlVKQvlTtMKqqkuSyxl6EeMeY1pLRZ6jMyqYFJzJFbq7Mjb5EIuLGL11JkFbfHNpV2y-JxhbaMs4gU1hHoqfP8o-w2YwEcop-HbOq7fFZvHim9yB4ExxHX3_W6ULfig-QZxcMHnDQ_HZDFMP8SV61pk-wqvju0ZfrzZfLj-WN7cfri8vbkrLuUilEJ2tmGBWdExRwYmqm85gKxmVhEhKgEihKmvqhljFG8wttx0jecg0glZ0jd4fdKe5yXeyMKZgej0FN5jwoL1x-t_O6HZ66-91hVm-lJJZ4e1RIfi7GWLSg4sW-t6M4OeoieSUYsKzpTV68wjd-3lJKFM1x0wIKUim6gNlg48xQHdyU2G9BKsfB6uXYDVZRl___ZvT4J8kM3B7APYxmS2cABOSsz38ryyIrthSjytOpN2ZoGGkvwDTb8TP</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2850466762</pqid></control><display><type>article</type><title>Factors Associated with Extended-spectrum β-lactamase-producing Enterobacteria Isolated from Respiratory Samples</title><source>J-STAGE Free</source><source>MEDLINE</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Matsumoto, Hiroyuki ; Komiya, Kosaku ; Ichihara, Shogo ; Nagaoka, Yuhei ; Yamanaka, Marimu ; Nishiyama, Yoshiki ; Hiramatsu, Kazufumi ; Kadota, Jun-ichi</creator><creatorcontrib>Matsumoto, Hiroyuki ; Komiya, Kosaku ; Ichihara, Shogo ; Nagaoka, Yuhei ; Yamanaka, Marimu ; Nishiyama, Yoshiki ; Hiramatsu, Kazufumi ; Kadota, Jun-ichi</creatorcontrib><description>Objective Although extended-spectrum β-lactamase (ESBL)-producing bacteria are a global threat, as they may cause respiratory infection, the factors associated with the isolation of these bacteria from sputum remain unclear. We therefore explored the factors related to ESBL-producing Klebsiella pneumoniae and Escherichia coli isolated from sputum samples. Methods This study included consecutive patients admitted to our department from 2010 to 2021 with K. pneumoniae or E. coli isolated from their sputum. The patients were categorized into ESBL-producing and non-ESBL-producing groups, and the factors associated with ESBL-producing bacteria isolation were assessed using a binomial logistic regression analysis. Results We included 82 patients, and ESBL-producing pathogens were isolated from 23 (28%). The usage rates of cephem [odds ratio (OR) 4.000, 95% confidence interval (CI) 1.402-11.409, p=0.010], quinolone (OR 2.961, 95% CI 1.097-7.996, p=0.032), and macrolide (OR 4.273, 95% CI 1.518-12.028, p=0.006) in the past year were significantly higher in the ESBL-producing group than in the non-ESBL-producing group. The multivariate analysis revealed that the applications of cephem (adjusted OR: 4.130, 95% CI: 1.233-13.830, p=0.021) and macrolide (adjusted OR: 6.365, 95% CI: 1.922-21.077, p=0.002) was independently associated with the isolation of ESBL-producing bacteria. Conclusion A history of cephem and macrolide use can be considered a risk factor for ESBL-producing bacteria isolation from sputum samples. Physicians need to consider these risk factors when determining antibiotics for the treatment of patients with respiratory infections.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.0690-22</identifier><identifier>PMID: 36476547</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Bacteria ; beta-Lactamases ; Enterobacteriaceae ; Escherichia coli ; Escherichia coli Infections - drug therapy ; Humans ; Internal medicine ; Klebsiella Infections - drug therapy ; Klebsiella pneumoniae ; macrolide ; Multivariate analysis ; odds ratio ; Original ; quinolone ; Respiratory tract infection ; Risk Factors ; Sputum ; β Lactamase</subject><ispartof>Internal Medicine, 2023/07/15, Vol.62(14), pp.2043-2050</ispartof><rights>2023 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2023</rights><rights>Copyright © 2023 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c556t-66fc1464c6f49365298bfa0c743722732e27691ca8b2c95b05c5cf42c14ab6313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400397/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400397/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1877,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36476547$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsumoto, Hiroyuki</creatorcontrib><creatorcontrib>Komiya, Kosaku</creatorcontrib><creatorcontrib>Ichihara, Shogo</creatorcontrib><creatorcontrib>Nagaoka, Yuhei</creatorcontrib><creatorcontrib>Yamanaka, Marimu</creatorcontrib><creatorcontrib>Nishiyama, Yoshiki</creatorcontrib><creatorcontrib>Hiramatsu, Kazufumi</creatorcontrib><creatorcontrib>Kadota, Jun-ichi</creatorcontrib><title>Factors Associated with Extended-spectrum β-lactamase-producing Enterobacteria Isolated from Respiratory Samples</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>Objective Although extended-spectrum β-lactamase (ESBL)-producing bacteria are a global threat, as they may cause respiratory infection, the factors associated with the isolation of these bacteria from sputum remain unclear. We therefore explored the factors related to ESBL-producing Klebsiella pneumoniae and Escherichia coli isolated from sputum samples. Methods This study included consecutive patients admitted to our department from 2010 to 2021 with K. pneumoniae or E. coli isolated from their sputum. The patients were categorized into ESBL-producing and non-ESBL-producing groups, and the factors associated with ESBL-producing bacteria isolation were assessed using a binomial logistic regression analysis. Results We included 82 patients, and ESBL-producing pathogens were isolated from 23 (28%). The usage rates of cephem [odds ratio (OR) 4.000, 95% confidence interval (CI) 1.402-11.409, p=0.010], quinolone (OR 2.961, 95% CI 1.097-7.996, p=0.032), and macrolide (OR 4.273, 95% CI 1.518-12.028, p=0.006) in the past year were significantly higher in the ESBL-producing group than in the non-ESBL-producing group. The multivariate analysis revealed that the applications of cephem (adjusted OR: 4.130, 95% CI: 1.233-13.830, p=0.021) and macrolide (adjusted OR: 6.365, 95% CI: 1.922-21.077, p=0.002) was independently associated with the isolation of ESBL-producing bacteria. Conclusion A history of cephem and macrolide use can be considered a risk factor for ESBL-producing bacteria isolation from sputum samples. Physicians need to consider these risk factors when determining antibiotics for the treatment of patients with respiratory infections.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Bacteria</subject><subject>beta-Lactamases</subject><subject>Enterobacteriaceae</subject><subject>Escherichia coli</subject><subject>Escherichia coli Infections - drug therapy</subject><subject>Humans</subject><subject>Internal medicine</subject><subject>Klebsiella Infections - drug therapy</subject><subject>Klebsiella pneumoniae</subject><subject>macrolide</subject><subject>Multivariate analysis</subject><subject>odds ratio</subject><subject>Original</subject><subject>quinolone</subject><subject>Respiratory tract infection</subject><subject>Risk Factors</subject><subject>Sputum</subject><subject>β Lactamase</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkd1u1DAQhS0EosvCK6BI3HCT4vg3vkJVtYVKlSrxc205zmTXqyRObafQ1-JBeCYcdllBuRlfzDdnjucgVFT4nFRCvXNjgjCafoDWWTfCORYKl4Q8QauKMlVKQvlTtMKqqkuSyxl6EeMeY1pLRZ6jMyqYFJzJFbq7Mjb5EIuLGL11JkFbfHNpV2y-JxhbaMs4gU1hHoqfP8o-w2YwEcop-HbOq7fFZvHim9yB4ExxHX3_W6ULfig-QZxcMHnDQ_HZDFMP8SV61pk-wqvju0ZfrzZfLj-WN7cfri8vbkrLuUilEJ2tmGBWdExRwYmqm85gKxmVhEhKgEihKmvqhljFG8wttx0jecg0glZ0jd4fdKe5yXeyMKZgej0FN5jwoL1x-t_O6HZ66-91hVm-lJJZ4e1RIfi7GWLSg4sW-t6M4OeoieSUYsKzpTV68wjd-3lJKFM1x0wIKUim6gNlg48xQHdyU2G9BKsfB6uXYDVZRl___ZvT4J8kM3B7APYxmS2cABOSsz38ryyIrthSjytOpN2ZoGGkvwDTb8TP</recordid><startdate>20230715</startdate><enddate>20230715</enddate><creator>Matsumoto, Hiroyuki</creator><creator>Komiya, Kosaku</creator><creator>Ichihara, Shogo</creator><creator>Nagaoka, Yuhei</creator><creator>Yamanaka, Marimu</creator><creator>Nishiyama, Yoshiki</creator><creator>Hiramatsu, Kazufumi</creator><creator>Kadota, Jun-ichi</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230715</creationdate><title>Factors Associated with Extended-spectrum β-lactamase-producing Enterobacteria Isolated from Respiratory Samples</title><author>Matsumoto, Hiroyuki ; Komiya, Kosaku ; Ichihara, Shogo ; Nagaoka, Yuhei ; Yamanaka, Marimu ; Nishiyama, Yoshiki ; Hiramatsu, Kazufumi ; Kadota, Jun-ichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c556t-66fc1464c6f49365298bfa0c743722732e27691ca8b2c95b05c5cf42c14ab6313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Bacteria</topic><topic>beta-Lactamases</topic><topic>Enterobacteriaceae</topic><topic>Escherichia coli</topic><topic>Escherichia coli Infections - drug therapy</topic><topic>Humans</topic><topic>Internal medicine</topic><topic>Klebsiella Infections - drug therapy</topic><topic>Klebsiella pneumoniae</topic><topic>macrolide</topic><topic>Multivariate analysis</topic><topic>odds ratio</topic><topic>Original</topic><topic>quinolone</topic><topic>Respiratory tract infection</topic><topic>Risk Factors</topic><topic>Sputum</topic><topic>β Lactamase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsumoto, Hiroyuki</creatorcontrib><creatorcontrib>Komiya, Kosaku</creatorcontrib><creatorcontrib>Ichihara, Shogo</creatorcontrib><creatorcontrib>Nagaoka, Yuhei</creatorcontrib><creatorcontrib>Yamanaka, Marimu</creatorcontrib><creatorcontrib>Nishiyama, Yoshiki</creatorcontrib><creatorcontrib>Hiramatsu, Kazufumi</creatorcontrib><creatorcontrib>Kadota, Jun-ichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsumoto, Hiroyuki</au><au>Komiya, Kosaku</au><au>Ichihara, Shogo</au><au>Nagaoka, Yuhei</au><au>Yamanaka, Marimu</au><au>Nishiyama, Yoshiki</au><au>Hiramatsu, Kazufumi</au><au>Kadota, Jun-ichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors Associated with Extended-spectrum β-lactamase-producing Enterobacteria Isolated from Respiratory Samples</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2023-07-15</date><risdate>2023</risdate><volume>62</volume><issue>14</issue><spage>2043</spage><epage>2050</epage><pages>2043-2050</pages><artnum>0690-22</artnum><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>Objective Although extended-spectrum β-lactamase (ESBL)-producing bacteria are a global threat, as they may cause respiratory infection, the factors associated with the isolation of these bacteria from sputum remain unclear. We therefore explored the factors related to ESBL-producing Klebsiella pneumoniae and Escherichia coli isolated from sputum samples. Methods This study included consecutive patients admitted to our department from 2010 to 2021 with K. pneumoniae or E. coli isolated from their sputum. The patients were categorized into ESBL-producing and non-ESBL-producing groups, and the factors associated with ESBL-producing bacteria isolation were assessed using a binomial logistic regression analysis. Results We included 82 patients, and ESBL-producing pathogens were isolated from 23 (28%). The usage rates of cephem [odds ratio (OR) 4.000, 95% confidence interval (CI) 1.402-11.409, p=0.010], quinolone (OR 2.961, 95% CI 1.097-7.996, p=0.032), and macrolide (OR 4.273, 95% CI 1.518-12.028, p=0.006) in the past year were significantly higher in the ESBL-producing group than in the non-ESBL-producing group. The multivariate analysis revealed that the applications of cephem (adjusted OR: 4.130, 95% CI: 1.233-13.830, p=0.021) and macrolide (adjusted OR: 6.365, 95% CI: 1.922-21.077, p=0.002) was independently associated with the isolation of ESBL-producing bacteria. Conclusion A history of cephem and macrolide use can be considered a risk factor for ESBL-producing bacteria isolation from sputum samples. Physicians need to consider these risk factors when determining antibiotics for the treatment of patients with respiratory infections.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>36476547</pmid><doi>10.2169/internalmedicine.0690-22</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-2918
ispartof Internal Medicine, 2023/07/15, Vol.62(14), pp.2043-2050
issn 0918-2918
1349-7235
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10400397
source J-STAGE Free; MEDLINE; PubMed Central; PubMed Central Open Access
subjects Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antibiotics
Bacteria
beta-Lactamases
Enterobacteriaceae
Escherichia coli
Escherichia coli Infections - drug therapy
Humans
Internal medicine
Klebsiella Infections - drug therapy
Klebsiella pneumoniae
macrolide
Multivariate analysis
odds ratio
Original
quinolone
Respiratory tract infection
Risk Factors
Sputum
β Lactamase
title Factors Associated with Extended-spectrum β-lactamase-producing Enterobacteria Isolated from Respiratory Samples
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T12%3A03%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20Associated%20with%20Extended-spectrum%20%CE%B2-lactamase-producing%20Enterobacteria%20Isolated%20from%20Respiratory%20Samples&rft.jtitle=Internal%20Medicine&rft.au=Matsumoto,%20Hiroyuki&rft.date=2023-07-15&rft.volume=62&rft.issue=14&rft.spage=2043&rft.epage=2050&rft.pages=2043-2050&rft.artnum=0690-22&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.0690-22&rft_dat=%3Cproquest_pubme%3E2850466762%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2850466762&rft_id=info:pmid/36476547&rfr_iscdi=true